Gene
NUTM1
NUTM1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (16), Actionable biomarkers (1), Trial mentions (24), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NUTM1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 2 of 11,460 | 0.02% |
| 2022 | 5 of 8,285 | 0.06% | 4 of 13,598 | 0.03% |
| 2021 | 2 of 8,692 | 0.02% | 4 of 15,045 | 0.03% |
| 2020 | 1 of 7,640 | 0.01% | 3 of 14,459 | 0.02% |
| 2019 | 2 of 7,300 | 0.03% | 3 of 12,159 | 0.02% |
| 2018 | 0 of 6,927 | 0.00% | 2 of 11,854 | 0.02% |
| 2017 | 0 of 6,558 | 0.00% | 0 of 11,595 | 0.00% |
Showing 10 of 37 years.
Assay-provider ledger (16)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| ABCAM | Reagent supplier | Clinical validationAnalytical validation | 2 | February 01, 2022 +1 undated |
| BECKMAN COULTER | Context dependent | Analytical validation | 1 | February 01, 2022 |
| BioGenex | Reagent supplier | Analytical validation | 2 | February 01, 2022 |
| CELL MARQUE | Reagent supplier | Analytical validation | 2 | February 01, 2022 |
| Cell Signaling | Reagent supplier | Clinical validationAnalytical validation | 3 | February 01, 2022 +1 undated |
Showing 5 of 16 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| BRD4-C15orf55 fusion | Bet Inhibitors | response-associated | NUT midline carcinoma | Cancer Genome Interpreter |
Trial mentions (24)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07863765 | Trial eligibility (AACT) |
| NCT07050186 | Trial eligibility (AACT) |
| NCT06527300 | Trial eligibility (AACT) |
| NCT04116359 | Trial eligibility (AACT) |
| NCT03106480 | Trial eligibility (AACT) |
Showing 5 of 24 trial mentions.
Target-disease associations (295)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46,XX sex reversal 1 | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY partial gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - myelodysplastic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 295 associations.
Vendor sourcing (94)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AOU S. Orsola Malpighi - Clinical Trial Office | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Locally advanced, relapsed or metastatic non-small cell lung cancer (NSCLC) - stage IIIB/IV according to 7th International Association for the Study of ... | View trial NCT03976518 |
| AOU S. Orsola Malpighi - Clinical Trial Office | Trial collaborator | Mentioned in trial textTrial free-text mention | NUT | View trial NCT03976518 |
| AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Locally advanced, relapsed or metastatic non-small cell lung cancer (NSCLC) - stage IIIB/IV according to 7th International Association for the Study of ... | View trial NCT03976518 |
| AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology | Trial collaborator | Mentioned in trial textTrial free-text mention | NUT | View trial NCT03976518 |
| Alleanza Contro il Cancro | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients with epithelial tumours of nasopharynx; nasal cavity and paranasal sinuses; salivary gland cancer in large and small salivary glands; and middl... | View trial NCT05483374 |
Showing 5 of 94 sourcing records.
Trial-cited literature (34)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. | Nature reviews. Clinical oncology | 2025 | 27 |
| Radiotherapy Outcomes and Prognostic Factors in Head and Neck NUT Carcinoma: A Single-Center Cohort Analysis. | Head & neck | 2025 | 1 |
| Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients. | Lung cancer (Amsterdam, Netherlands) | 2024 | 20 |
| Molecularly Defined Thoracic Neoplasms. | Advances in anatomic pathology | 2024 | 2 |
| Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. | Nature medicine | 2023 | 82 |
Showing 5 of 34 papers.
Literature-extracted relations (21)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Radiotherapy Outcomes and Prognostic Factors in Head and Neck NUT Carcinoma: A Single-Center Cohort Analysis. | 2025 |
| Head and Neck Neoplasms | Disease | associate |
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. | 2025 |
| Lung Diseases | Disease | associate |
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. | 2025 |
| Neoplasms | Disease | associate |
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. | 2025 |
| Neoplasms | Disease | associate |
Molecularly Defined Thoracic Neoplasms. | 2024 |
Showing 5 of 21 relation assertions.
Organizations publishing (136)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 7 | 2012 to 2025 |
| Novant Health | Hospital | 6 | 2015 to 2023 |
| Harvard Medical School | Academic | 4 | 2012 to 2025 |
| Lund University | Academic | 3 | 2015 to 2018 |
| Memorial Sloan Kettering Cancer Center | Hospital | 3 | 2018 to 2021 |
Showing 5 of 136 organizations.
Where NUTM1 appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- infectious disease
- measurement
- phenotype
- reproductive system or breast disease
288 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.